STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
How did STAA's recent EPS compare to expectations?
The most recent EPS for STAAR Surgical Co is $0.23, beating expectations of $-0.06.
How did STAAR Surgical Co STAA's revenue perform in the last quarter?
STAAR Surgical Co revenue for the last quarter is $0.23
What is the revenue estimate for STAAR Surgical Co?
According to 12 of Wall street analyst, the revenue estimate of STAAR Surgical Co range from $94.71M to $67.68M
What's the earning quality score for STAAR Surgical Co?
STAAR Surgical Co has a earning quality score of B+/50.620064. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does STAAR Surgical Co report earnings?
STAAR Surgical Co next earnings report is expected in 2026-08-11
What are STAAR Surgical Co's expected earnings?
STAAR Surgical Co expected earnings is $77.01M, according to wall-street analysts.
Did STAAR Surgical Co beat earnings expectations?
STAAR Surgical Co recent earnings of $93.52M beat expectations.